Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II.
Glutamate carboxypeptidase II may modulate excitatory neurotransmission through the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) and possibly other endogenous peptide substrates. To investigate the molecular properties of cloned human GCP II (hGCP II), we analyzed the NAAG-hydrolytic activity conveyed by transfection of a full-length hGCP II cDNA into PC3 cells, which do not express GCP II endogenously. Membrane fractions from these cells demonstrated activity with an apparent Km of 73 nM and Vmax of 35 pmol/(mg protein*min). Activity was inhibited by EDTA and stimulated by the addition of CoCl2. Addition of GCP II inhibitors beta-NAAG, quisqualic acid and 2-(phosphonomethyl)pentanedioic acid (PMPA) inhibited hydrolysis of 2.5 nM NAAG with IC50s of 201 nM, 155 nM and 98 pM, respectively. In competition experiments designed to infer aspects of hGCP II substrate selectivity, NAAG was the most potent alpha peptide tested, with an IC50 of 26 nM. Folate derivatives and some other gamma-glutamyl peptides showed comparable affinity to that of NAAG, also displaying IC50s in the low nM range. Taken together with previous evidence demonstrating their presence in GCP II-expressing tissues, these data suggest that both NAAG and folates are good candidate substrates for GCP II in vivo.
Luthi-Carter
R
R
Laboratory of Molecular and Developmental Neuroscience, Massachusetts General Hospital East, Room 2510, Charlestown, MA 02129, USA.
Barczak
A K
AK
Speno
H
H
Coyle
J T
JT
D000818:Animals; D000954:Antigens, Surface; D001667:Binding, Competitive / Q000502:physiology; D002268:Carboxypeptidases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D002614:Chelating Agents / Q000494:pharmacology; D003001:Cloning, Molecular; D003035:Cobalt / Q000494:pharmacology; D003374:Coumarins / Q000494:pharmacology; D004151:Dipeptides / Q000378:metabolism*; D004492:Edetic Acid / Q000494:pharmacology; D005492:Folic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D043425:Glutamate Carboxypeptidase II; D006634:Histamine H1 Antagonists / Q000378:metabolism*; D006801:Humans; D006868:Hydrolysis; D049934:Isocoumarins; D007700:Kinetics; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D009479:Neuropeptides / Q000378:metabolism*; D010436:Pepstatins / Q000494:pharmacology; D010618:Phenanthrolines / Q000494:pharmacology; D011471:Prostatic Neoplasms; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D013379:Substrate Specificity; D009435:Synaptic Transmission / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000201:enzymology
D000954:Antigens, Surface; D002614:Chelating Agents; D003374:Coumarins; D004151:Dipeptides; D006634:Histamine H1 Antagonists; D049934:Isocoumarins; D009479:Neuropeptides; D010436:Pepstatins; D010618:Phenanthrolines; D011480:Protease Inhibitors; D015842:Serine Proteinase Inhibitors; C014195:Streptomyces pepsin inhibitor; C027172:isospaglumic acid; D003035:Cobalt; C046235:3,4-dichloroisocoumarin; D005492:Folic Acid; C054774:3-carboxy-2,3-epoxypropionyl-leucylamido-(4-acetamido)butane; D004492:Edetic Acid; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D007930:Leucine; C031375:pepstatin; C025205:1,10-phenanthroline